Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

doi:10.1016/j.bmcl.2016.08.010

Bioorganic & Medicinal Chemistry Letters

Volume 26, Issue 19, 1 October 2016, Pages 4837-4841

https://doi.org/10.1016/j.bmcl.2016.08.010 Get rights and content

Abstract

The p53–MDM2 interaction is an anticancer drug target under investigation in the clinic. Our compound NVP-CGM097 is one of the small molecule inhibitors of this protein–protein interaction currently evaluated in cancer patients. As part of our effort to identify new classes of p53–MDM2 inhibitors that could lead to additional clinical candidates, we report here the design of highly potent inhibitors having a pyrazolopyrrolidinone core structure. The conception of these new inhibitors originated in a consideration on the MDM2 bound conformation of the dihydroisoquinolinone class of inhibitors to which NVP-CGM097 belongs. This work forms the foundation of the discovery of HDM201, a second generation p53–MDM2 inhibitor that recently entered phase I clinical trial.

Graphical abstract

References and notes (19)

N. Philippe et al.
Tetrahedron
(2003)
F. Mohamadi et al.
J. Comput. Chem.
(1990)
A. Burgess et al.
Frontiers in Oncology
(2016)
Y. Zhao et al.
J. Med. Chem.
(2015)
P.-C. Lv et al.
Curr. Med. Chem.
(2015)
K.K. Hoe et al.
Nat. Rev. Drug. Discovery
(2014)
S. Nag et al.
Curr. Med. Chem.
(2014)
M. Wade et al.
Nat. Rev. Cancer
(2013)
Q. Li et al.
Clin. Cancer Res.
(2013)
J.C. Carry et al.
Bioorg. Med. Chem. Lett.
(2013)
P. Furet et al.
Bioorg. Med. Chem. Lett.
(2012)
A. Vaupel et al.
Bioorg. Med. Chem. Lett.
(2014)

There are more references available in the full text version of this article.

Cited by (57)

Small molecules targeting protein–protein interactions for cancer therapy
2023, Acta Pharmaceutica Sinica B
Protein–protein interactions (PPIs) are fundamental to many biological processes that play an important role in the occurrence and development of a variety of diseases. Targeting the interaction between tumour-related proteins with emerging small molecule drugs has become an attractive approach for treatment of human diseases, especially tumours. Encouragingly, selective PPI-based therapeutic agents have been rapidly advancing over the past decade, providing promising perspectives for novel therapies for patients with cancer. In this review we comprehensively clarify the discovery and development of small molecule modulators of PPIs from multiple aspects, focusing on PPIs in disease, drug design and discovery strategies, structure-activity relationships, inherent dilemmas, and future directions.
Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma
2023, Cell Genomics
Amplification of MDM2 on supernumerary chromosomes is a common mechanism of P53 inactivation across tumors. Here, we investigated the impact of MDM2 overexpression on chromatin, gene expression, and cellular phenotypes in liposarcoma. Three independent regulatory circuits predominate in aggressive, dedifferentiated tumors. RUNX and AP-1 family transcription factors bind mesenchymal gene enhancers. P53 and MDM2 co-occupy enhancers and promoters associated with P53 signaling. When highly expressed, MDM2 also binds thousands of P53-independent growth and stress response genes, whose promoters engage in multi-way topological interactions. Overexpressed MDM2 concentrates within nuclear foci that co-localize with PML and YY1 and could also contribute to P53-independent phenotypes associated with supraphysiologic MDM2. Importantly, we observe striking cell-to-cell variability in MDM2 copy number and expression in tumors and models. Whereas liposarcoma cells are generally sensitive to MDM2 inhibitors and their combination with pro-apoptotic drugs, MDM2-high cells tolerate them and may underlie the poor clinical efficacy of these agents.
The role of the MDM2/p53 axis in antitumor immune responses
2023, Blood
Mouse double minute 2 homolog (MDM2) is a negative regulator of the tumor suppressor p53 and often highly expressed in acute myeloid leukemia (AML) and different solid tumors. Inactivating mutations in TP53, the gene encoding for p53, confers an unfavorable prognosis in AML and increases the risk for relapse after allogeneic hematopoietic cell transplantation (allo-HCT). We review the concept that manipulation of MDM2 and p53 could enhance immunogenicity of AML and solid tumor cells. Additionally, we discuss the mechanisms by which MDM2 and p53 regulate MHC class I and II expression, transcription of dsRNA of endogenous retroviruses, interferon responses, IL-15 production and TRAIL-receptor 1 and 2 expression on malignant cells. The direct effects of MDM2-inhibition or MDM2 deletion in effector T cells are discussed in the context of cancer immunotherapy. The preclinical findings are connected to clinical studies using MDM2-inhibition to enhance anti-tumor immunity in patients. In aggregate, this review summarizes current evidence supporting the use of MDM2-inhibition to restore p53, as well as direct effects of MDM2-inhibition on T cells as an emerging concept for combined anti-tumor immunotherapy against hematological malignancies and beyond.
Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer
2022, Seminars in Cell and Developmental Biology
As a post-translational modification that has pivotal roles in protein degradation, ubiquitination ensures that intracellular proteins act in a precise spatial and temporal manner to regulate diversified cellular processes. Perturbation of the ubiquitin system contributes directly to the onset and progression of a wide variety of diseases, including various subtypes of cancer. This highly regulated system has been for years an active research area for drug discovery that is exemplified by several approved drugs. In this review, we will provide an update of the main breakthrough scientific discoveries that have been leading the clinical development of ubiquitin-targeting therapies in the last decade, with a special focus on E1 and E3 modulators. We will further discuss the unique challenges of identifying new potential therapeutic targets within this ubiquitous and highly complex machinery, based on available crystallographic structures, and explore chemical approaches by which these challenges might be met.
Small-molecule MDM2 inhibitors in clinical trials for cancer therapy
2022, European Journal of Medicinal Chemistry
Citation Excerpt :
Siremadlin, also named NVP-HDM201, discovered by scientists in Novartis, is a novel potent MDM2 inhibitor, bearing imidazolopyrrolidinone core [47], which is currently being evaluated in 10 clinical trials for the treatment of myelofibrosis, acute myeloid leukemia, colorectal cancer, advanced cancer, metastatic cancer, malignant solid tumor, myelodysplastic syndrome, liposarcoma, uveal melanoma, non-small cell lung carcinoma, triple-negative breast cancer, renal cell carcinoma, advanced solid, and hematological TP53 wt tumors (Table 1). In 2016, Furet et al. in Novartis reported the discovery of compound 18 (Fig. 11A) after screening the Novartis compound collection and further optimization of the hit compound, which effectively inhibited MDM2 with an IC50 value of 0.13 nM [47]. The cocrystal structure of 18 with MDM2 indicated that 18 fitted into the three typical active pockets of MDM2 (Leu-26, Trp-23, and Phe-19, Fig. 11B) [47].
Disruption of the MDM2-p53 protein-protein interaction by small-molecule inhibitors has been highly pursued by many academic laboratories and pharmaceutical companies as a promising strategy for cancer therapy. To date, based on the explanation of the cocrystal structure of MDM2 with p53, many highly potent and selective small-molecule MDM2 inhibitors have been successfully discovered and nine of them are currently under different clinical trials for cancer therapy. Herein, we will review the function of MDM2 and provide a comprehensive and updated overview of small-molecule MDM2 inhibitors in different clinical phases for cancer therapy, especially focusing on the identification and optimization, and preclinical/clinical studies of these clinical-stage MDM2 inhibitors. Challenges regarding acquired resistance and potential toxicity of MDM2 inhibitors to normal tissues and outlook are also briefly discussed, which will further guide the design of new small-molecule MDM2 inhibitors.
A survey of applications of tetrahydropyrrolo-3,4-azoles and tetrahydropyrrolo-2,3-azoles in medicinal chemistry
2021, Advances in Heterocyclic Chemistry
Tetrahydropyrrolo-3,4-azoles and tetrahydropyrrolo-2,3-azoles represent an interesting family of heterocycles that offer potential utility in drug design as either scaffolds or pharmacophoric elements. The tetrahydropyrrolo[3,4-c]pyrazole ring system is the most explored representative of this class of heterobicycle which is represented in the marketed dipeptidyl peptidase-4 inhibitor omarigliptin and the Phase 2 clinical candidate danusertib, an Aurora kinase inhibitor. In this chapter, we provide an overview of the synthesis of tetrahydropyrrolo-3,4-azoles and summarize their applications in drug design and discovery. In contrast, the tetrahydropyrrolo-2,3-azole series has been only sparsely explored with no significant systematic study or defined application in drug design.

View all citing articles on Scopus

View full text

Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument

Abstract

Graphical abstract

Tetrahedron

J. Comput. Chem.

Frontiers in Oncology

J. Med. Chem.

Curr. Med. Chem.

Nat. Rev. Drug. Discovery

Curr. Med. Chem.

Nat. Rev. Cancer

Clin. Cancer Res.

Bioorg. Med. Chem. Lett.

Bioorg. Med. Chem. Lett.

Bioorg. Med. Chem. Lett.